Copyright 2016 American Medical Association. All Rights Reserved.
In Reply We thank Dr D’Ascanio and colleagues for their comments on our study.1 We agree on the points raised regarding heterogeneous subcategories within T3 glottic cancer category, failure to specify the type of surgery performed, and the challenges of reporting functional outcomes. We believe the fundamental issue is the incomplete nature of the data source with which we worked. Many of the important characteristics and variables described above were either not readily available or not reliable.
Al-Gilani M, Haughey B, Piccirillo JF. Appropriate Treatment of T3 Glottic Cancer—Reply. JAMA Otolaryngol Head Neck Surg. 2017;143(3):318. doi:10.1001/jamaoto.2016.3238
Customize your JAMA Network experience by selecting one or more topics from the list below.